Open AccessAccess to Clinical Trials for Adolescents and Young Adults With Cancer: A Meta-Research Analysis
Author(s) -
Teresa de Rojas,
Anouk Neven,
Mitsumi Terada,
Miriam García-Abós,
Lucas Moreno,
Nathalie Gaspar,
Julien Péron
Publication year - 2019
Publication title -
jnci cancer spectrum
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.345
H-Index - 10
ISSN - 2515-5091
DOI - 10.1093/jncics/pkz057
Subject(s) - medicine , clinical trial , age limit , young adult , cancer , pediatrics , demography , sociology
Background The 18-year-old age limit for inclusion in clinical trials constitutes a hurdle for adolescents and young adults (AYAs) with cancer. We analyzed the impact of this age barrier on the access of AYAs to cancer trials and novel therapies. Methods ClinicalTrials.gov was searched to identify all the trials including patients with 10 malignancies relevant for AYAs (January 2007 to July 2018). The trials were categorized as pediatric (patients <18 y), adult (≥18 y), and transitional (including adult and pediatric patients). Transitional trials with a lower limit between 12 and 18 years and an upper limit younger than 40 years were considered AYA-specific. Results Of 2764 identified trials, 2176 were included: 79% adult, 19% transitional, 2% pediatric. Five trials were AYA-specific. The proportion of academic trials was higher for transitional (69%; 288 of 421) than for adult trials (48%; 832 of 1718) (P < .0001). The total number of new trials increased over the years (156 in 2007; 228 in 2017); however, the number of transitional trials remained stable. The availability of trials increased with age, with a major increase at age 18 years: at age 17 years, 20% (442 of 2176) of trials were potentially accessible vs 95% (2075 of 2176) at 18 years. For trials investigating targeted therapies, this increase was 460% (197 trials available at age 17 years; 901 at 18 years) and for immunotherapies, 1200% (55 at age 17 years; 658 at 18 years). Conclusions AYAs have limited access to cancer trials and innovative therapies, with no improvement over the last decade. The 18-years-old age limit continues to be a major hurdle. Our findings are consistent with the internationally supported idea that age inclusion criteria in oncological trials should be changed.